Val-cit-PAB-OH_COA_18846_MedChemExpress
超高效液相色谱-串联质谱法测定人血浆中精氨酸及衍生物含量
超高效液相色谱-串联质谱法测定人血浆中精氨酸及衍生物含量田晔;江骥;胡蓓;薛金萍;王洪允【摘要】建立了超高效液相色谱-串联质谱(UPLC-MS/MS)法同时测定使用艾普拉唑后人血浆中二甲基精氨酸(ADMA)、对称二甲基精氨酸(SDMA)、单甲基精氨酸(NMMA)、瓜氨酸(Cit)和L-精氨酸(L-Arg)的浓度.采用HILIC亲水相互作用色谱和非衍生化的蛋白沉淀法进行分离分析,色谱柱选取Waters Atlantic HILIC柱(2.1 mm×50 mm×3μm),流动相由乙腈(含0.5％乙酸和0.025％三氟乙酸)-水(含0.5％乙酸和0.025％三氟乙酸)(85:15,v/V)组成,流速0.25 mL/min.采用多反应离子监测(MRM)模式,以电喷雾离子源(ESI)正离子方式检测.结果显示,ADMA、SDMA、NMMA、L-Arg和Cit的线性关系良好,相关系数r均大于0.994 0;ADMA、SDMA和NMMA的线性范围为0.1～5 mmol/L,L-Arg和Cit的线性范围为10～250 mmol/L;5种氨基酸的日内、日间精密度均小于15％,准确度在85％～115％之间.该方法快速、简便、灵敏,可为相关疾病的临床诊断提供一种高效的检测手段.【期刊名称】《质谱学报》【年(卷),期】2016(037)005【总页数】7页(P446-452)【关键词】超高效液相色谱-串联质谱(UPLC-MS/MS);艾普拉唑;蛋白沉淀法;亲水性色谱【作者】田晔;江骥;胡蓓;薛金萍;王洪允【作者单位】福州大学化学学院,福建省功能材料工程研究中心,福建省光动力治疗药物与诊疗工程技术研究中心,福建福州350108;中国医学科学院北京协和医院临床药理中心,北京100730;中国医学科学院北京协和医院临床药理中心,北京100730;中国医学科学院北京协和医院临床药理中心,北京100730;福州大学化学学院,福建省功能材料工程研究中心,福建省光动力治疗药物与诊疗工程技术研究中心,福建福州350108;中国医学科学院北京协和医院临床药理中心,北京100730【正文语种】中文【中图分类】O657.63一氧化氮是人体重要的信使分子，L-精氨酸(L-Arg)在一氧化氮全酶(NOS)的催化下，产生一氧化氮(NO)和瓜氨酸(Cit)[1-2]。
依达拉奉右莰醇联合阿替普酶治疗急性缺血性脑卒中的疗效观察
J Apoplexy and Nervous Diseases, October 2023, Vol 40，No. 10依达拉奉右莰醇联合阿替普酶治疗急性缺血性脑卒中的疗效观察李春颖1， 鞠东升1， 潘澍潇1， 朱辉2， 靳颖1摘要： 目的 观察依达拉奉右莰醇联合阿替普酶治疗急性缺血性脑卒中（AIS ）的疗效性和安全性。
方法 收集2020年11月―2022年4月松原吉林油田医院收治的AIS 患者共计124例，随机分为实验组（阿替普酶静脉溶栓+依达拉奉右莰醇组）和对照组（阿替普酶静脉溶栓组），对比治疗效果。
结果 实验组治疗总有效率为82.3%，高于对照组的64.5%，差异有统计学意义（P < 0.05）。
其溶栓后不同阶段NIHSS 评分结果（5.40 ± 3.82）分、（4.14 ± 3.44）分、（0.57 ± 0.99）分均低于对照组，差异有统计学意义（P < 0.05）。
两组患者治疗期间均未发生药物不良反应。
结论 依达拉奉右莰醇联合阿替普酶治疗AIS 患者临床疗效确切。
关键词： 依达拉奉右莰醇； 阿替普酶； 急性缺血性脑卒中； 疗效中图分类号：R743.3 文献标识码：AEfficacy of edaravone dexborneol combined with alteplase in treatment of acute ischemic stroke LI Chunying ，JU Dongsheng ， PAN Shuxiao ， et al. （Songyuan Jilin Oilfield Hospital ， Songyuan 138000， China ）Abstract ： Objective To investigate the efficacy and safety of edaravone dexborneol combined with alteplase in the treatment of acute ischemic stroke （AIS ）.Methods The data were collected from 124 patients with AIS who were admitted to our hospital from November 2020 to April 2022. The patients were randomly divided into experimental group （intravenous thrombolysis with alteplase + treatment with edaravone dexborneol ） and control group （intravenous thrombolysis with al‑teplase ）， and the two groups were compared for efficacy.Results The overall response rate in the experimental group was sig‑nificantly higher than that in the control group （82.3% vs 64.5%， P < 0.05）. The National Institutes of Health Stroke Scale scores at different stages after thrombolysis were significantly lower in the experimental group （5.40 ± 3.82， 4.14 ± 3.44， and 0.57 ± 0.99） than in the control group （P < 0.05）. No adverse drug reactions were observed in the two groups during the treat‑ment.Conclusion Edaravone dexborneol combined with alteplase has definite clinical efficacy in the treatment of AIS.Key words ： Edaravone dexborneol ； Alteplase ； Acute ischemic stroke ； Efficacy 脑卒中是全球致残的主要原因和第二大死亡原因［1］，至少50%幸存者将遗留残疾［2］。
Val-cit-PAB-OH_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jun.-08-2017Print Date:Jun.-08-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Val-cit-PAB-OHCatalog No. :HY-12362CAS No. :159857-79-11.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:C18H29N5O4Molecular Weight:379.45CAS No. :159857-79-14. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature: 4°C, stored under nitrogenShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
机械通气临床应用指南(中华重症医学分会2024)
机械通气临床应用指南中华医学会重症医学分会（2024年）引言重症医学是探讨危重病发生发展的规律，对危重病进行预防和治疗的临床学科。
器官功能支持是重症医学临床实践的重要内容之一。
机械通气从仅作为肺脏通气功能的支持治疗起先，经过多年来医学理论的发展及呼吸机技术的进步，已经成为涉及气体交换、呼吸做功、肺损伤、胸腔内器官压力及容积环境、循环功能等，可产生多方面影响的重要干预措施，并主要通过提高氧输送、肺脏爱护、改善内环境等途径成为治疗多器官功能不全综合征的重要治疗手段。
机械通气不仅可以依据是否建立人工气道分为“有创”或“无创”，因为呼吸机具有的不同呼吸模式而使通气有众多的选择，不同的疾病对机械通气提出了具有特异性的要求，医学理论的发展及循证医学数据的增加使对呼吸机的临床应用更加趋于有明确的针对性和规范性。
在这种条件下，不难看出，对危重病人的机械通气制定规范有明确的必要性。
同时，多年临床工作的积累和多中心临床探讨证据为机械通气指南的制定供应了越来越充分的条件。
中华医学会重症医学分会以循证医学的证据为基础，采纳国际通用的方法，经过广泛征求看法和建议，反复仔细探讨，达成关于机械通气临床应用方面的共识，以期对危重病人的机械通气的临床应用进行规范。
重症医学分会今后还将依据医学证据的发展及新的共识对机械通气临床应用指南进行更新。
指南中的举荐看法依据2024年ISF提出的Delphi分级标准(表1)。
指南涉及的文献依据探讨方法和结果分成5个层次，举荐看法的举荐级别依据Delphi分级分为A E级，其中A 级为最高。
表1 Delphi分级标准举荐级别A 至少有2项I级探讨结果支持B 仅有1项I级探讨结果支持C 仅有II级探讨结果支持D 至少有1项III级探讨结果支持E 仅有IV级或V探讨结果支持探讨课题分级I 大样本，随机探讨，结果清楚，假阳性或假阴性的错误很低II 小样本，随机探讨，结果不确定，假阳性和/或假阴性的错误较高III 非随机，同期比照探讨IV 非随机，历史比照和专家看法V 病例报道，非比照探讨和专家看法危重症患者人工气道的选择人工气道是为了保证气道通畅而在生理气道与其他气源之间建立的连接，分为上人工气道和下人工气道，是呼吸系统危重症患者常见的抢救措施之一。
碱基切除修复抑制剂甲氧胺联合β-榄香烯治疗恶性脑胶质瘤的实验研究
序言β-榄香烯属国家二类非细胞毒性抗肿瘤新药，临床研究证实其对包括脑胶质瘤在内的多种肿瘤疗效确切，且无其他传统化疗药常有的骨髓抑制、肝肾功能损害等毒副作用。
但目前临床应用的榄香烯乳注射液因其存在静脉炎发生率很高、剂型性质不稳定等缺点，其进一步的应用受到了较大的限制。
碱基切除修复抑制剂甲氧胺（Methoxyamine），可通过裂解核酸内切酶破坏DNA碱基切除修复过程，从而抑制肿瘤细胞对损伤作用的修复反应。
据此，可认为抑制DNA 碱基切除修复可能是增强肿瘤细胞化疗敏感性的潜在靶点，目前多项实验报道也已证实了甲氧胺可增强烷化剂和放疗的抗肿瘤效果。
近年来，通过纳米技术构建的纳米脂质体在提高药物溶解度、增加药物稳定性、降低药物副作用、缓控释给药等方面较普通的脂质体有了显著的提高。
研究表明，纳米脂质体对正常细胞和组织无损伤作用，并可长时间吸附于靶细胞周围，因此使药物能充分向靶组织渗透，也可以通过静电吸附效应与细胞膜接触而融合而进入细胞内。
因此将药物包封于纳米脂质体被认为可以改变被包封药物的体内分布，提高药物治疗指数，降低药物毒性。
基于增强β-榄香烯的疗效，减少毒副作用的目的，本课题研究内容分两部分：（一）联合碱基切除修复抑制剂甲氧胺，探讨是否在体内外抗瘤活性上具有协同作用，以期减少榄香烯用量，降低毒副反应，为其在临床的应用提供实验和理论依据。
（二）、利用纳米脂质体技术构建新型的β-榄香烯-纳米脂质体药物传递系统，初步探讨其体外抗瘤活性。
II碱基切除修复抑制剂甲氧胺联合β-榄香烯治疗恶性脑胶质瘤的实验研究中文摘要胶质瘤是成人神经系统最常见的原发性肿瘤，手术全切除率很低，复发率高，当前多种治疗效果仍不理想。
榄香烯属国家二类非细胞毒性抗肿瘤新药，临床研究发现其对多种肿瘤疗效确切，而且还具有提高和改善机体免疫功能，与放化疗协同作用等独特效果。
但是肿瘤细胞具有强大的DNA损伤修复机制，会对化疗药物产生抗性。
因此抑制这种内在的DNA修复过程，如碱基切除修复抑制剂甲氧胺的联合应用有利于提高化疗药物的抗瘤效果。
血清生物标志物在缺血缺氧性脑病新生儿中的研究进展
血清生物标志物在缺血缺氧性脑病新生儿中的研究进展兰雪，崔艳芳，陈国萍，于嘉，肇颖新(哈尔滨医科大学附属第一医院新生儿科，黑龙江哈尔滨150001)摘要：治疗性低温疗法作为低氧缺血性脑病(hypoxic ischemic encephalopathy,HIE)治疗标准的广泛引入，给临床医生带来了越来越大的压力，要求他们对发生的低氧损伤(hypoxic injury,H I)的程度和随之而来的脑病的严重程度做出早期和准确的评估。
然而，目前还没有任何一种基于血液的标志物足以检测HI或预测预后。
许多炎症蛋白、神经元特异性蛋白和MicroRNA表达可预测HIE病情变化，这些变化在出生的几小时至几天内迅速演变。
将临床数据与生化检测结果相结合是目前改善新生儿HIE的检测和预测结局的最可能途径。
本文总结了目前对HIE血清生物标志物的研究，显示了其预测HIE预后的潜力。
关键词：血清生物标记物；新生儿；缺血缺氧性脑病；研究进展中图分类号：R7222文献标识码：AResearch Progresses of Serum Biomarkers in Neonateswith Hypoxic Ischemic EncephalopathyLAN Xue,CUI Yanfang,CHEN Guoping,YU Jia,ZHAO Yingxin (Department of Neonatology,The First Affiliated Hospital of Harbin Medical University,Harbin150001,China) Abstract：The widespread introduction of therapeutic hypothermia as a standard of care for hypoxic ischemic encephalopathy(HIE)has created an increasing pressure on clinicians to make an early and accurate asse s ment ofthe degree of hypoxicinjury(HI)that occurs and the severity ofthe accompanyingencephalopathy.However,none of the blood-based markersisyetgoodenoughto accuratelydetectsignificantHIorpredictoutcomes.HIEisa s ociatedwith manypredictablechanges in inflammatory proteins,neuron-specific proteins,and MicroRNA expressions that evolve rapidly withinhoursto daysafterbirth.Thecombination of clinical data and biochemicaltestresultsis currentlythe mostpromising approachtoimprovethe detection and prediction of neonatal HIE outcomes.This paper summarizes the current research on SERUM biomarkers of HIE and shows its potentialtopredictHIEresults.Key words:；Serum biomarkers；Newborn；Hypoxic ischemic encephalopathy；Progress在新生儿低氧缺血性脑病(hypoxic ischemic encephalopathy,HIE)的管理中，最大的难点是对于HIE的预测、检测和分级，分级的结果会影响治疗干预的方式。
咖啡酸片---肿瘤CIT的应用
中华肿瘤杂志，2018，40（9）Cancer Res 2007; 67: (10). May 15, 2007
巨核细胞凋亡是CIT发生的关键因素
CIT主要是化疗药物对巨核系细胞产生抑制作用。研究显示，化疗药物对于巨核细胞的前体作用最强，对于干细胞和成熟巨核细胞作用相对较弱。
咖啡酸口服半衰期近1小时。主要在肝脏和血浆中代谢，主要生成甲基化、氧化、缩合类的代谢产物。
口服给药，以尿排泄为主，少部分经粪和胆汁排泄。24小时内尿排出97.8%，尿、粪总排量为口服药量的99.5%。
药代动力学研究
吸收Байду номын сангаас
分布
代谢
排泄
——《南京药学院学报》3H-咖啡酸的体内过程研究 徐黻本，邵鹤生，潘尚仁 等，1980年 第一期
Elting LS,et al.J Clin Oncol.2001 Feb 15;19(4):1137-46.Bonadonna Get al. N Engl JMed.1995 Apr 6;332(14):901-6
Elting,et al.j ClinOncol.2001.19.1137
CIT的临床危害
国内独家
拥有原料药和制剂两项发明专利，生产技术先进，产品质量优异，临床疗效显著。
主要由小肠吸收，30分钟吸收超过半量,1小时吸收约70%。由胆汁排入十二指肠的原形药及其代谢物有75%左右仍又被小肠吸收，形成肠-肝循环
咖啡酸血浆蛋白结合率低，多数以游离形式存在。在血液和肾脏中分布较高，在其他脏器中的分布依次为子宫、肝肺、卵巢、脾脏、骨髓、垂体等。
放化疗联合使CIT程度更严重，恢复更慢
胸骨及骨盆大面积照射对PLT的影响
依达拉奉右莰醇通过铁死亡-脂质过氧化通路对脑出血大鼠神经保护的作用机制
实验研究依达拉奉右莰醇通过铁死亡-脂质过氧化通路对脑出血大鼠神经保护的作用机制毛权西，李作孝△摘要：目的探讨依达拉奉右莰醇对脑出血大鼠的神经保护作用及血肿周围脑组织脂质过氧化的影响。
方法将128只SD大鼠随机分为假手术组、脑出血组、依达拉奉组和依达拉奉右莰醇组，每组32只。
除假手术组外，其余组大鼠构建急性脑出血模型，依达拉奉组、依达拉奉右莰醇组于造模后分别腹腔注射依达拉奉6mg/kg、依达拉奉右莰醇7.5mg/kg，每12h注射1次，假手术组和脑出血组腹腔注射等量生理盐水。
术后1d、3d、7d和14d按Garcia评分标准进行神经功能评分，HE染色观察血肿周围脑组织病理变化，化学荧光法检测血肿周围脑组织活性氧（ROS）含量，微量酶标法检测血肿周围脑组织还原型谷胱甘肽（GSH）含量，蛋白免疫印迹法检测血肿周围脑组织谷胱甘肽过氧化物酶4（GPX4）、长链脂酰辅酶A合成酶4（ACSL4）和磷脂胆碱酰基转移酶3（LPCAT3）表达。
结果与假手术组比较，脑出血组大鼠神经功能评分降低，血肿周围脑组织出现大量炎性细胞浸润及神经细胞变性，ROS含量、ACSL4和LPCAT3蛋白表达水平升高，GSH含量、GPX4蛋白表达水平降低（P＜0.05）；与脑出血组比较，依达拉奉组和依达拉奉右莰醇组大鼠神经功能评分升高，血肿周围脑组织病理损伤明显减轻，ROS含量、ACSL4和LPCAT3蛋白表达水平降低，GSH含量、GPX4蛋白表达水平增加（P＜0.05）；依达拉奉右莰醇组干预效果优于依达拉奉组（P＜0.05）；除假手术组外，其余各组均在术后3d时变化最明显，术后7d、14d逐渐恢复（P＜0.05）。
结论依达拉奉右莰醇可能通过调节脑出血大鼠神经细胞铁死亡相关蛋白的表达，减少脑组织脂质过氧化，抑制神经细胞铁死亡，从而发挥脑保护作用。
关键词：依达拉奉右莰醇；依达拉奉；脑出血；铁死亡；脂质过氧化中图分类号：R743.34文献标志码：A DOI：10.11958/20221777Neuroprotective mechanism of edaravone dexborneol in rats with cerebral hemorrhage throughferroptosis-lipid peroxidation pathwayMAO Quanxi,LI Zuoxiao△Department of Neurology,the Affiliated Hospital of Southwest Medical University,Luzhou646000,China△Corresponding Author E-mail:Abstract:Objective To investigate the neuroprotective effect of edaravone dexborneol on cerebral hemorrhage in rats and the effect of lipid peroxidation on perihematomal brain tissue.Methods A total of128SD rats were randomly divided into the sham-operated group,the cerebral hemorrhage group,the edaravone group and the edaravone dexborneol group, with32rats in each group.The acute cerebral hemorrhage model was constructed in all groups except for the sham-operated group.The edaravone group and edaravone dexamphene group were injected intraperitoneally with6mg/kg of edaravone and edaravone dexamphene7.5mg/kg,one injection every12hours.The sham-operated group and the cerebral hemorrhage group were injected intraperitoneally with equal amounts of saline.The neurological function was scored according to Garcia score at1d,3d,7d,and14d after surgery.Brain tissue around hematoma was stained with HE staining.Chemo fluorescence assay was used to observe pathological changes and reactive oxygen species(ROS)content of brain tissue around hematoma.Micro enzyme labeling assay was used to detect glutathione(GSH)content of brain tissue around hematoma.The expression levels of glutathione peroxidase4(GPX4),long-chain lipid acyl-coenzyme A synthase4(ACSL4) and phospholipid choline acyltransferase3(LPCAT3)in brain tissue around hematoma were detected by protein immunoblotting.Results Compared with the sham-operated group,neurological function scores were decreased in the cerebral hemorrhage group.Massive inflammatory cell infiltration and neuronal degeneration in brain tissue around hematoma were found,and ROS content,ACSL4and LPCAT3protein expression level increased.GSH content and GPX4 protein expression level decreased in the cerebral hemorrhage group(P＜0.05).Compared with the cerebral hemorrhage group,neurological function scores were increased,histopathological damage around the hematoma was significantly基金项目：泸州市人民政府-西南医科大学科技战略合作基金项目（2018LZXNYD-ZK17）作者单位：西南医科大学附属医院神经内科（邮编646000）作者简介：毛权西（1990），男，硕士在读，主要从事神经免疫方向研究。
国内中国期刊的英文缩写
Abstr. Papers Am. Chem. Soc. Abstracts of Papers. American Chemical Society Acta Academiae Aboensis Acta Academiae AboensisActa Chem. Scand. Acta Chemica ScandinavicaActa Crystallograph. Acta CrystallographicaActa Hydrobiol. Sinica Acta Hydrobiolica SinicaActa Hydrochim. Hydrobiol. Acta Hydrochimica et HydrobiologicaActa Med. Scand. Acta Medica ScandinavicaActa Pharmaceutica Fennica Acta Pharmaceutica FennicaAmbio AmbioAnalyst AnalystAnalyt. Bioanalyt. Chem. Analytical and Bioanalytical Chemistry Analyt. Biochem. Analytical BiochemistryAnalyt. Chem. Analytical ChemistryAnalyt. Chim. Acta Analytica Chimica ActaAnalyt. Lett. Analytical LettersAnalyt. Sci. Analytical Sciences——仅供参考Angew. Chem. Int. Ed. Angewandte Chemie–International EditionAnn. Allergy Annals of AllergyAnn. Internal Med. Annals of Internal MedicineAnn. Limnol. Annales de Limnologie–International Journal ofLimnologyAnn. N.Y. Acad. Sci. Annals. New York Academy of SciencesAnn. Rev. Microbiol. Annual Review of MicrobiologyAnn. Rev. Pharmacol. Toxicol. Annual Review of Pharmacology and ToxicologyArch. Hydrobiol.–Algol. Stud. Archiv für Hydrobiologie–Algological Studies Arch. Hydrobiol.–Beih. Ergebn. Limnol. Archiv für Hydrobiologie–Beiheft Ergebnisse derLimnologieArch. Hydrobiol.–Monogr. Beit. Archiv für Hydrobiologie–Monographische Beitr?ge Arch. Int. Pharmacodyn. Ther. Archives Internationales de Pharmacodynamie et deTherapieArch. Lat. Nutr. Archivos Latinoamericanos de NutricionArch. Microbiol. Archiv für MicrobiologieArch. Pharmacol. Archives of Pharmacology——仅供参考Arch. Pharmazie Archiv der PharmazieArch. Toxicol. Archives of ToxicologyArizona Acad. Sci. Arizona Academy of Science. JournalArzneim.-Forsch.–Drug Res. Arzneimittel-Forschung–Drug ResearchAssoc. S.E. Biol. Bull. The Association of Southeastern Biologists Bulletin Aust. J. Biol. Sci. Australian Journal of Biological SciencesAust. J. Dairy Technol. Australian Journal of Dairy TechnologyAust. J. Ecol. Australian Journal of EcologyBiofizikaBiofuturBiol. Control Biological ControlBiol. Fertility Soils Biology and Fertility of SoilsBiol. Pharmaceut. Bull. Biological and Pharmaceutical BulletinBiologia BiologiaBiological Res. Biological ResearchBiologie Géologie Biologie GéologieBiologische Rudschau Biologische RudschauBiomed. Chromat. Biomedical Chromatography——仅供参考Biomed. Environ. Sci. Biomedical and Environmental SciencesBioorg. Medicinal Chem. Bioorganic & Medicinal ChemistryBioorg. Medicinal Chem. Lett. Bioorganic & Medicinal Chemistry Letters Biophys. J. Biophysical JournalBioresource Technol. Bioresource TechnologyBiosci. Biotechnol. Biochem. Bioscience Biotechnology and Biochemistry Bioscience BioscienceBiosensors & Bioelectronics Biosensors & BioelectronicsBull. Jap. Soc. Sci. Fish. Bulletin of the Japanese Society of Scientific Fisheries Bull. Korean Chem. Soc. Bulletin. Korean Chemical SocietyBull. Mar. Sci. Bulletin of Marine ScienceBull. Minn. Acad. Sci. The Bulletin of the Minnesota Academy of Science Bull. Natl. Sci. Mus. (Tokyo) Bulletin. National Science Museum (Tokyo)Bull. Pan Am. Health Org. Bulletin of the Pan American Health Organization Bull. Soc. Bot. France Bulletin de la Société Botaniqúe de FranceByull. Izobret. Byulleten Izobretiniia——仅供参考Can. J. Anaes. Canadian Journal of AnaesthesiaCan. J. Biochem. Canadian Journal of BiochemistryCan. J. Biochem. Physiol. Canadian Journal of Biochemistry and Physiology Can. J. Bot. Canadian Journal of BotanyCan. J. Chem. Canadian Journal of ChemistryCan. J. Comp. Med. Canadian Journal of Comparative Medicine Can. J. Comp. Med. Vet. Sci. Canadian Journal of Comparative Medicine andVeterinary ScienceChem. Biol. Chemistry and Biology (London)Chem-Biol. Inter. Chemico-Biological InteractionsChem. Britain Chemistry in BritainChem. Commun. Chemical CommunicationsChem. Int. Chemistry InternationalChem. Pharmaceut. Bull. Chemical & Pharmaceutical BulletinChem. Res. Toxicol. Chemical Research in ToxicologyChem. Rev. Chemical Reviews——仅供参考Chem. Soc. Rev. Chemical Society Reviews Chemosphere ChemosphereChimia ChimiaChinese Biochem. J. Chinese Biochemical JournalChinese J. Analyt. Chem. Chinese Journal of Analytical Chemistry Chromatographia ChromatographiaCirc. Res. Circulation ResearchCirc. Shock Circulatory ShockCurr. Biol. Current BiologyCurr. Med. Chem. Current Medicinal ChemistryCurr. Microbiol. Current MicrobiologyCurr. Opinion Microbiol. Current Opinion in Microbiology Curr. Opinion Struct. Biol. Current Opinion in Structural Biology Curr. Pharmaceut. Design Current Pharmaceutical DesignCurr. Sci. Current ScienceCytobios Cytobios——仅供参考Dansk Vet. Tidsskr. Dansk Veterin?r TidsskriftDeep-Sea Res. Part 1 Deep-Sea Research Part 1–Oceanographic ResearchPapersDeut. Lebens.-Rund. Deutsche Lebensmittal-RundschauDev. Hydrobiol. Developments in HydrobiologyDis. Aquat. Org. Diseases of Aquatic OrganismsDNA Seq. DNA SequenceDokl. Akad. Nauk Doklady Akademii NaukEcologyEMBO J.Environ. Health Perspect. Environmental Health PerspectivesEnviron. Int. Environment InternationalEnviron. Microbiol. Environmental MicrobiologyEnviron. Poll. Environmental PollutionEnviron. Res. Environmental ResearchEnviron. Rev. Environmental ReviewEnviron. Sci. Poll. Res. Environmental Science and Pollution ResearchEnviron. Sci. Res. Environmental Science Research——仅供参考Environ. Sci. Technol. Environmental Science and TechnologyEnviron. Technol. Environmental TechnologyEnviron. Technol. Lett. Environmental Technology LettersEnviron. Toxicol. Environmental ToxicologyEnviron. Toxicol. Chem. Environmental Toxicology and Chemistry Environ. Toxicol. Pharmacol. Environmental Toxicology and Pharmacology Environ. Toxicol. Water Qual. Environmental Toxicology and Water Quality Enzyme Microbial Technol. Enzyme and Microbial TechnologyEvolutionExp. Bot.FASEB J. FASEB JournalFauna FaunaFauna Flora Fauna och FloraFEBS Lett. FEBS (Federation of European Biochemical Societies)LettersFed. Proc. Federation ProceedingsFEMS Microbiol. Ecol. FEMS (Federation of European MicrobiologicalSocieties) Microbiology-EcologyFEMS Microbiol. Lett. FEMS (Federation of European MicrobiologicalSocieties) Microbiology Letters——仅供参考FEMS Microbiol. Rev. FEMS (Federation of European MicrobiologicalSocieties) Microbiology ReviewsField Stud. Field StudiesFinsk Tidskr. Finsk TidskriftFinsk Vet. Tidskr. Finsk Veterin?rtidskriftFish Physiol. Biochem. Fish Physiology and BiochemistryFish. Sci. Fisheries ScienceFlicker FlickerGeneHealth Environ. Digest Health & Environment DigestHelvetica Chim. Acta Helvetica Chimica ActaHepatology HepatologyHeterocycles HeterocyclesHuman Ecol. Risk Assess. Human and Ecological Risk AssessmentHuman Exp. Toxicol. Human & Experimental ToxicologyHuman Nature Human NatureHydrobiol. J. (Gidrobiologicheskii Zh.) Hydrobiological Journal (Gidrobiologicheskii Zhurnal)——仅供参考Hydrobiologia HydrobiologiaHydrol. Processes Hydrological ProcessesIEE Proc.–Sci. Measure. Technol. IEE Proceedings–Science, Measurement & Technology IMA. J. Math. Appl. Med. Biol. IMA (Institute of Mathematics and Its Applications)Journal of Mathematics Applied in Medicine &BiologyIndian J. Chem. Section A–Inorg. Bio-Inorg.Physical Theoret. Analyt. Chem. Indian Journal of Chemistry Section A–Inorganic Bio-Inorganic Physical Theoretical & Analytical ChemistryIowa State Coll. Vet. Iowa State College VeterinarianIsrael J. Plant Sci. Israel Journal of Plant SciencesIzv. Akad. Nauk. SSSR. Ser. Biol. Izvestiia Akademii Nauk SSSR, Seriia Biologicheskaia J. Adv. Oxidation Technol. Journal of Advanced Oxidation TechnologiesJ. Agric. Food Chem. Journal of Agricultural and Food ChemistryJ. Agric. S. Aust. Journal of Agriculture (South Australia)J. Agric. West. Aust. Journal of Agriculture of Western AustraliaJ. Allergy The Journal of Allergy——仅供参考J. Allergy Clin. Immunol. Journal of Allergy and Clinical ImmunologyJ. Am. Chem. Soc. Journal. American Chemical SocietyJ. Am. Soc. Mass Spec. Journal of the American Society for Mass Spectrometry J. Am. Vet. Med. Assoc. Journal of the American Veterinary Medical Association J. Am. Water Works Assoc. Journal of the American Water Works AssociationJ. Analyt. Toxicol. Journal of Analytical ToxicologyJ. Antibiot. Journal of AntibioticsJ. Appl. Bacteriol. Journal of Applied BacteriologyJ. Biotechnol. Journal of BiotechnologyJ. Cancer Res. Clin. Oncol. Journal of Cancer Research and Clinical OncologyJ. Catalysis Journal of CatalysisJ. Cell Sci. Journal of Cell ScienceJ. Chart. Inst. Water Environ. Manage. Journal of the Chartered Institution of Water andEnvironmental ManagementJ. Chem. Ecol. Journal of Chemical EcologyJ. Chem. Soc., Chem. Commun. Journal. Chemical Society. Chemical CommunicationsJ. Chem. Soc. Chem. Comp. Journal. Chemical Society. Chemical CompoundsJ. Chem. Soc., Perkin Trans. 1 Journal of the Chemical Society–Perkin Transactions 1 J. Chromat. Journal of ChromatographyJ. Chromat. A Journal of Chromatography AJ. Chromat. B, Analyt. Technol. Biomed.Life Sci. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life SciencesJ. Chromat. B: Biomed. Sci. Appl. Journal of Chromatography B: Biomedical Sciences andApplicationsJ. Clin. Microbiol. Journal of Clinical MicrobiologyJ. Ecol.Eng.J. Exp. Mar. Biol. Ecol. Journal of Experimental Marine Biology and Ecology J. Fish Biol. Journal of Fish BiologyJ. Fish Dis. Journal of Fish DiseasesJ. Food Hygienic Soc. Japan Journal of the Food Hygienic Society of JapanJ. Freshwater Ecol. Journal of Freshwater EcologyJ. Gastroenterol. Hepatol. Journal of Gastroenterology and HepatologyJ. Gen. Microbiol. Journal of General MicrobiologyJ. Great Lakes Res. Journal of Great Lakes ResearchJ. Health Sci. Journal of Health ScienceJ. Health Toxicol. Journal of Health Toxicology (Chinese)J. High Resol. Chromat. Journal of High Resolution Chromatography andChromatography Communications (West Germany) J. Ind. Microbiol. Journal of Industrial MicrobiologyJ. Ind. Microbiol. Biotechnol. Journal of Industrial Microbiology & Biotechnology J. Infect. Dis. Journal of Infectious DiseasesJ. Infection Journal of InfectionJ. Mol. Evol. Journal of Molecular EvolutionJ. Natl. Cancer Inst. Journal of the National Cancer InstituteJ. Natural Products Journal of Natural ProductsJ. Natural Toxins Journal of Natural ToxinsJ. Neurochem. Journal of NeurochemistryJ. Org. Chem. Journal of Organic ChemistryJ. Parasitol. Journal of ParasitologyJ. Pharmaceut. Biomed. Anal. Journal of Pharmaceutical and Biomedical AnalysisJ. Pharmaceut. Sci. Journal of Pharmaceutical SciencesJ. Pharmaceut. Soc. Jap. Journal of the Pharmaceutical Society of JapanJ. Pharmacol. Exp. Therapeut. Journal of Pharmacology and Experimental Therapeutics J. Photochem. Photobiol. A–Chem. Journal of Photochemistry and PhotobiologyA-ChemistryJ. Photochem. Photobiol. B–Biol. Journal of Photochemistry and Photobiology B-Biology J. Phycol. Journal of PhycologyJ. Planar Chromat. Journal of Planar ChromatographyJ. Toxicol.AquaJap. J. Ecol. Japanese Journal of EcologyJap. J. Limnol. Japanese Journal of LimnologyJap. J. Toxicol. Environ. Health Japanese Journal of Toxicology and EnvironmentalHealthJersey J. The Jersey JournalKemia-Kemi Kemia-KemiL?kartidningen L?kartidningenLake Reservoir Manage. Lake and Reservoir ManagementLakeLine LakeLineLancet The LancetLC-GC Europe LC-GC EuropeLC-GC N. Am. LC-GC North AmericaLett. Appl. Microbiol. Letters in Applied MicrobiologyLett. Peptide Sci. Letters in Peptide ScienceLife Chem. Rep. Life Chemistry ReportsLife Sci. Pharmacol. Lett. Life Sciences Including Pharmacology LettersLipidsMagy. áMar. Ecol.Mem. Inst. Osw. Cruz Memorias do Instituto Oswaldo CruzMh. Vet. Med. Monatshefte fuer Veterinaermedizin Microbial Ecol. Microbial EcologyMicrobiol. Immunol. Microbiology and Immunology Microbiol. Rev. Microbiological ReviewsMicrobiol. Sci. Microbiological SciencesMicrobiology Microbiology (Mikrobiologiya)Microbiology–SGM Microbiology–Society for General Microbiology Microbios MicrobiosMicrobios Lett. Microbios LettersMicroscopy Res. Technique Microscopy Research and Technique Mikrobiol. Zh. Mikrobiologicheskii Zh.Mikrokosmos MikrokosmosMilk Producer The Milk ProducerMinn. Botan. Ser. IV Minnesota Botanical Series IVNatureNaval Res. Rev. Naval Research ReviewsNebFacts NebFactsNed. Tijdschr. Geneesk. Nederlands Tijdschrift voor Geneeskunde Nephrol. Dial. Transpl.. Nephrology Dialysis Transplantation Neurochem. Res. Neurochemical ResearchNeuron NeuronNeuropharmacol. NeuropharmacologyNeuroToxicol. NeurotoxicologyNew Engl. J. Med. New England Journal of MedicineNew J. Chem. New Journal of ChemistryNew Phytol. New PhytologistNewsl. Aust. Soc. Limnol. Newsletter of the Australian Society of Limnology Nippon Suis. Gak. Nippon Suisan GakkaishiNorsk Veterinaertidsskrift Norsk VeterinaertidsskriftNZ. J. Mar. Freshwater Res. New Zealand Journal of Marine and Freshwater Research NZ. Vet. J. New Zealand Veterinary JournalOecologiaOpheliaOrg. Lett.PathologyPest. Sci.Pharmacol. Therapeut. Pharmacology & TherapeuticsPharmacol. Toxicol. Pharmacology & ToxicologyPharmacology PharmacologyPharmazie PharmaziePhilosoph. Trans. Roy. Soc. London Ser. B.Biol. Sci. Philisophical Transactions of the Royal Society of London Series B–Biological SciencesPhotosyn. Res. Photosynthesis Research Phycol. Res. Phycological ResearchPhycol. Soc. Am. News Bull. Phycological Society of American News Bulletin Phycologia PhycologiaPhykos PhykosPhysiol. Plant. Physiologica PlantarumPhysiol. Rev. Physicological ReviewsPhytochem. PhytochemistryPhytomedicine PhytomedicinePhyton–Int. J. Exp. Bot. Phyton. International Journal of Experimental BotanyPlant Sci.PlantaPlasmidProtein Sci. Protein ScienceProtist ProtistPub. Health Lab. Serv. Microbiol. Digest Public Health Laboratory Service Microbiology Digest Pub. Health Rep. Public Health ReportsPub. Works Public WorksPure Appl. Chem. Pure and Applied ChemistryRapid Commun. Mass Spec. Rapid Communications in Mass SpectrometryRed Tide Newsl. Red Tide NewsletterRegul. Rivers: Res. & Manage. Regulated Rivers: Research & ManagementRemote Sens. Environ. Remote Sensing of EnvironmentRes. Commun. Chem. Pathol. Pharmacol. Research Communications in Chemical Pathology &PharmacologyRes. Vet. Sci. Research in Veterinary ScienceResource Geology Resource GeologyRev. Biol. Trop. Revista de Biologia TropicalRev. Dept. água Esgotos S?o Paulo Revista do Departmento de água e Esgotos de S?o PauloSarsiaSci. Am.Sci. Bull.Sci. Total Environ. Science of the Total EnvironmentSci. Vet. Sciences VeterinairesScience ScienceSem. Dialy. Seminars in DialysisSewage Ind. Wastes Sewage and Industrial WastesSewage Works Eng. Sewage Works Engineering and Municipal Sanitation Sk?rg?rd Sk?rg?rdSkr. Danm. Fiskeri-Havunders. Skrifter Danmarks Fiskeri- og Havundersogelser Soc. Neurosci. Abstr. Society for Neuroscience. AbstractsSoil Biol. Biochem. Soil Biology and BiochemistrySouth African Journal of Science South African Journal of ScienceSpec. Acta A–Mol. Biomol. Spec. Spectrochimica Acta Part A Molecular BiomolecularSpectroscopyStads Havnein. Stads-og HavneingeniorenStruc. Biol. Structural BiologySynlettTalantaTelopeaTetrahed.TibtechToxicol.Toxicol. Lett. Toxicology LettersToxicol. Mech. Methods Toxicology Mechanisms and MethodsToxicol. Sci. Toxicological SciencesToxicologic Pathol. Toxicologic PathologyToxicologist The ToxicologistToxicology ToxicologyToxicon ToxiconTrans. Am. Fish. Soc. Transactions. American Fisheries SocietyTrans. Inst. Br. Geogr. Transactions. Institute of British Geographers Trans. Roy. Soc. S. Afr. Transactions. Royal Society of South Africa Trans. Roy. Soc. Trop. Med. Hyg. Transactions. Royal Society of Tropical Medicine andHygieneTransplan. Proc. Transplantation ProceedingsTrends Biochem. Sci. Trends in Biochemical SciencesTrends Plant Sci. Trends in Plant ScienceUmschauUrtVandVet. Med.Vet. Res.Water Environ. Res. Water Environment ResearchWater Poll. Control Water Pollution ControlWater Poll. Control Fed. J. Water Pollution Control Federation. JournalWater Quality Res. J. Canada Water Quality Research Journal of CanadaWater Res. Water ResearchWater Res. Action Water Research in ActionWater Resources Manage. Water Resources ManagementWater S. Afr. Water South AfricaWater Sci. Technol. Water Science & TechnologyWater Sci. Technol. Water Supply Water Science & Technology: Water Supply Water Sewage Works Water and Sewage WorksWater Treat. Exam. Water Treatment and ExaminationWeed Sci. Weed ScienceWildlife Soc. Bull. Wildlife Society. BulletinWissen. Z. Wilhelm-Pieck Uni. Rostock Wissenschaftliche Zeitschrift derWilhelm-Pieck-Universitaet Rostock。
基于网络药理学预测白藜芦醇治疗阿尔茨海默症的关键潜在靶点
基于网络药理学预测白藜芦醇治疗阿尔茨海默症的关键潜在靶点田晓燕 江思瑜 张睿 许顺江 李国风*【摘要】目的通过网络药理学预测白藜芦醇(resveratrol,RSV)治疗阿尔茨海默症(Alzheimer's disease,AD)的关键靶点。
方法 利用TCMSP数据库检索含RSV的中药，并对其性味、归经和功效进行归纳分析。
利用SwissTargetPrediction、SEA、HERB数据库预测RSV作用靶点；利用GeneCards、OMIM、TTD、DisGeNRT 数据库检索AD靶点；取RSV的作用靶点与AD靶点的交集为潜在治疗靶点。
利用DAVID数据库进行潜在治疗靶点的GO分析。
利用STRING数据库获取潜在治疗靶点的KEGG富集分析和蛋白质交互作用（protein-protein interaction, PPI），并用Cytoscape绘制PPI网络图。
AlzData数据库验证AD关键靶点变化。
SwissDock网站对RSV与关键蛋白进行分子对接。
结果含RSV中药的性味为苦味最多；归经中入肝经最多；功效中清热解毒功效最多。
RSV预测靶点388个，AD靶点1624个，交集靶点119个。
KEGG富集通路中的阿尔兹海默症通路共富集到27个蛋白。
AlzData数据库分析发现AD患者表达发生变化的蛋白。
分子对接结果发现，RSV与丝氨酸/苏氨酸激酶(serine/threonine kinase 1, AKT1)、白介素-6(interleukin-6, IL-6)、连环蛋白-1(β-catenin, CTNNB1)、肿瘤坏死因子(tumor necrosis factor, TNF)均有较好的结合能力。
结论网络药理分析结果显示RSV对AD的治疗是多靶点、多通路的，可为后续研究方向提供参考。
【关键词】 网络药理学；白藜芦醇；阿尔兹海默症；分子对接中图分类号 R285文献标识码 A 文章编号1671-0223(2023)24-1879-08Predicting the key potential targets of resveratrol in the treatment of Alzheimer's disease based on network pharmacology Tian Xiaoyan, Jiang Siyu, Zhang Rui, Xu Shunjiang, Li Guofeng. Chengde Medical University, Chengde 067000, China【Abstract】Objective Key targets of resveratrol (RSV) in the treatment of Alzheimer's disease (AD) are predicted by network pharmacology. Methods The traditional Chinese medicines which contain RSV were searched by the TCMSP database, and their property and flavor, meridian distribution and phamacologic action were summarized and analyzed. The targets of RSV were predicted by SwissTargetPrediction, SEA and HERB databases. The targets of AD were retrieved using GeneCards, OMIM, TTD and DisGeNRT databases. The intersection targets of RSV and AD were taken as the potential therapeutic targets.Analysis gene ontology (GO) annotations of potential therapeutic targets by biological information annotation database (DAVID). Did KEGG cluster analysis and protein interactions (PPIs) of potential therapeutic targets in STRING database, and mapped PPI networks in Cytoscape. Verified changes of AD key targets in AlzData database.Docking RSV and key proteins in SwissDock website. Results The most Tropism of taste of the traditional Chinese medicines that contain RSV: bitter, cold, in the liver. And the main phamacologic action is clearing away heat and toxic materials.There are 388 predicted targets of RSV,1624 targets of AD, 119 intersection targets. Alzheimer's pathway in KEGG enriched pathway was enriched to 27 proteins. The proteins which expression changed of AD patients was analysised in AlzData database. The results of molecular docking showed that RSV had good binding ability with AKT1, IL-6, CTNNB1 and TNF. Conclusion The results of network pharmacological analysis show that the treatment of AD by RSV is multi-target and multi-pathway, which can provide reference for subsequent research directions.【Key words】 Network pharmacology; Resveratrol; Alzheimer's disease; Molecular docking作者单位：067000 河北省承德市，承德医学院研究生学院 （田晓燕、李国风）；河北医科大学第一医院中心实验室（江思瑜、张睿、许顺江）；河北省疾病预防控制中心药物研究所（李国风）*通讯作者现代科学研究认为，阿尔兹海默症（Alzheimer disease，AD）是一种不可逆的退行性神经疾病，临床上多以记忆力障碍、执行能力障碍以及人格变化等为特征，是老年性痴呆的最主要因素。
依达拉奉右莰醇治疗缺血性脑卒中的研究进展
- 179 -①滨州医学院附属医院神经内科 山东 滨州 256600通信作者：鹿树军依达拉奉右莰醇治疗缺血性脑卒中的研究进展席娅琳① 汪临华① 鹿树军① 【摘要】 缺血性脑卒中是脑血管疾病中的常见病，严重可导致高级认知及运动障碍，甚至死亡。
缺血性脑卒中的治疗方法主要包括早期溶栓和保护神经细胞等治疗，然而目前神经保护剂的临床疗效有待考证，大多数神经保护剂仍未得出有益的证据。
新型双靶点复合型神经保护剂依达拉奉右莰醇（ED）可抑制诱导型一氧化氮合酶（iNOS）和肿瘤坏死因子-α（TNF-α）的表达，降低自由基过氧化亚硝基阴离子（ONOO -）水平，从而改善缺血性脑卒中所致的神经损伤症状、功能障碍及活动障碍，本文将对ED 的作用机制及其应用发展做一综述，并对ED 的临床应用进行展望，为后续的用药提供指导。
【关键词】 缺血性脑卒中 自由基清除剂 神经保护剂 依达拉奉右莰醇 Research Progress of Edaravone Dexborneol in the Treatment of Ischemic Stroke/XI Yalin, WANG Linhua, LU Shujun. //Medical Innovation of China, 2024, 21(10): 179-183 [Abstract] Ischemic stroke is a common type of cerebrovascular disease that can lead to advanced cognitive and motor deficits and even death. The treatment of ischemic stroke mainly includes early thrombolysis and neuroprotection. However, the clinical efficacy of neuroprotective agents remains to be verified, and most neuroprotective agents have not yet received useful evidence. Edaravone Dexborneol (ED), a new dual-target neuroprotective agent, can inhibit the expression of inducible nitric oxide synthase (iNOS) and tumor necrosis factor-α(TNF-α), reduce the level of peroxynitrite anion (ONOO -), and improve the symptoms of nerve injury, dysfunction, and activity disorder caused by ischemic stroke. This article will review the mechanism of ED and its application development, and prospect the clinical application of ED, so as to provide guidance for subsequent medication. [Key words] Ischemic stroke Free radical scavenger Neuroprotective agent Edaravone Dextrogenol First-author's address: Department of Neurology, Binzhou Medical University Hospital, Binzhou 256600, China doi：10.3969/j.issn.1674-4985.2024.10.041 脑卒中已成为我国居民寿命的“第一杀手”，其中，急性缺血性脑卒中（acute ischemic stroke，AIS）约占我国脑卒中的70%，为最常见的卒中类型[1-2]。
α-常春藤皂苷调控SREBP1
doi:10.3971/j.issn.1000-8578.2023.22.1503α-常春藤皂苷调控SREBP1/FASN 通路抑制非小细胞肺癌的恶性表型常毓真1,2，杨浩1,2，黄钢1,2α-Hederin Regulates SREBP1/FASN Pathway and Inhibits Malignant Phenotype of Non-small Cell Lung CancerCHANG Yuzhen 1,2, YANG Hao 1,2, HUANG Gang 1,21. Shanghai University of Traditional Chinese Medicine, Shanghai 200120, China;2. Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, ChinaCorrespondingAuthors:HUANGGang,E-mail:*******************.cn;YANGHao,E-mail:***************.cnAbstract: Objective To explore the regulative effect of α-Hederin on the proliferation and invasion of NSCLC and investigate its related molecular mechanism. Methods After A549 and HCC-1833 cells were treated with a concentration gradient of α-Hederin for 24 and 48 h, the OD 450nm was detected by using CCK8 assays, and the IC 50 was calculated. The A549 and HCC-1833 cells were divided into the blank control and α-Hederin groups in accordance with IC 50 values. Cell proliferation was detected by EdU assays, and cell cycle transformation and cell apoptosis were detected by flow cytometry. Cell mobility was detected by using Transwell and scratch assays. SREBP1 and FASN protein expression levels were detected through Western blot analysis, and cell lipid accumulation was detected via oil red O staining. Results The survival rate of lung cancer cells decreased significantly with the increase of α-Hederin concentration, and the IC 50 values of A549 and HCC-1833 cells at 48 h were 15 and 25 μg/ml, respectively. Compared with the blank control group, cells proliferation and migration were significantly inhibited, cells were blocked in the G 1/S phase, the apoptosis rate increased, and the protein expression and lipid accumulation of SREBP1/FASN significantly reduced after α-Hederin treatment. Conclusion α-Hederin can inhibit the proliferation and migration, G 1/S phase transition and induce the apoptosis of NSCLC cells and hinder the malignant progression of NSCLC by downregulating the expression of SREBP1 and FASN and reducing the accumulation of cell lipids. Key words: α-Hederin; NSCLC; SREBP1; FASN; Lipid accumulationFunding: The National Natural Science Foundation of China (No. 82127807); Shanghai Key Laboratory of Molecular Imaging (No. 18DZ2260400); The National Key Research and Development Pregram of China (No. 2020YFA0909000)Competing interests: The authors declare that they have no competing interests.摘 要：目的 探讨α-常春藤皂苷对非小细胞肺癌细胞增殖和侵袭的调控作用及其相关分子机制。
干扰素诱导蛋白16的生物学机制研究进展
网络出版时间：２０２４－０１－３０１６：３５：３５ 网络出版地址：ｈｔｔｐｓ：／／ｌｉｎｋ．ｃｎｋｉ．ｎｅｔ／ｕｒｌｉｄ／３４．１０８６．Ｒ．２０２４０１２９．１１０６．００８干扰素诱导蛋白１６的生物学机制研究进展崔 京１，李逸雯１，刘艳飞１，２，刘 癑１（１．国家中医心血管病临床医学研究中心，中国中医科学院西苑医院，２．中国中医科学院西苑医院老年医学二科，北京 １０００９１）收稿日期：２０２３－０１－０５，修回日期：２０２３－０４－１０基金项目：中医药特色人才培养工程（岐黄工程）青年岐黄学者项目；国家自然科学基金优秀青年科学基金（Ｎｏ８２０２２０７６）作者简介：崔 京（１９９７－），女，硕士生，研究方向：中西医结合抗动脉粥样硬化，Ｅ ｍａｉｌ：ｃｕｉｊｉｎｇ８１７３＠１６３．ｃｏｍ；刘 癑（１９８２－），男，博士，主任医师，教授，博士生导师，研究方向：中西医结合抗动脉粥样硬化，通信作者，Ｅ ｍａｉｌ：ｌｉｕｙｕｅｈｅａｒｔ＠ｈｏｔｍａｉｌ．ｃｏｍｄｏｉ：１０．１２３６０／ＣＰＢ２０２３０１０１４文献标志码：Ａ文章编号：１００１－１９７８（２０２４）０２－０２１９－０６中国图书分类号：Ｒ３４１ １；Ｒ３３９ ３８；Ｒ９７７ ６；Ｒ９７８ ７摘要：干扰素诱导蛋白１６（ｉｎｔｅｒｆｅｒｏｎγ ｉｎｄｕｃｉｂｌｅｐｒｏｔｅｉｎ１６，ＩＦＩ１６）是人类ＰＹＨＩＮ（ｐｙｒｉｎａｎｄＨＩＮｄｏｍａｉｎ ｃｏｎｔａｉｎｉｎｇｐｒｏ ｔｅｉｎ）家族（也称干扰素诱导蛋白Ｐ２００家族）成员之一，在人体器官组织中广泛存在，参与细胞周期调控、细胞衰老、细胞凋亡及免疫反应等多种生物过程。
不同生理及病理状态下，ＩＦＩ１６的含量及定位均会发生改变，近年来研究发现，其在抗病毒、肿瘤、炎性疾病及其他多种疾病发生发展过程中可能发挥重要作用。
该文对其机制及其在疾病中的研究现状进行综述，以期为深入研究ＩＦＩ１６提供参考。
关键词：干扰素诱导蛋白１６；ＰＹＨＩＮ；细胞衰老；生物学机制；疾病；进展开放科学（资源服务）标识码（ＯＳＩＤ）： 干扰素诱导蛋白１６（ｉｎｔｅｒｆｅｒｏｎ ｉｎｄｕｃｉｂｌｅｐｒｏｔｅｉｎ１６，ＩＦＩ１６）是目前所知的第一个参与干扰素 β（ｉｎｔｅｒｆｅｒｏｎ β，ＩＦＮ β）诱导的ＰＹＨＩＮ（ｐｙｒｉｎａｎｄＨＩＮｄｏｍａｉｎ ｃｏｎｔａｉｎｉｎｇｐｒｏ ｔｅｉｎ）蛋白，是ＩＦＮ γ诱导蛋白Ｐ２００家族成员之一。
考来维仑治疗胆汁酸性腹泻有效性和安全性的Meta分析
lh#LunX%MeKX!f2020，D yc；39(6)：806-11 -806-!.论著.考来维仑治疗胆汁酸性腹泻有效性和安全性的Meta分析杨楠1,高洁1,刘娟2，黄蓉2,陈洪2（1.东南大学医学院，江苏南京210009；2,东南大学附属中大医院消化内科，江苏南京210009）&摘要］目的：对新一代胆汁酸螯合剂考来维仑治疗胆汁酸性腹泻（BAD）的有效性和安全性进行Meta分析，并对比考来维仑和考来烯胺在剂型、剂量、不良反应、价格等方面的优劣。
方法：在PubMed、Web l Science* Medline*EMB A SE*Cochrane librae*CNKI和万方等数据库检索文献，纳入使用考来维仑治疗BAD的相关资料。
应用Statu14.0计算考来维仑治疗有效率和不良反应发生率。
根据非随机对照研究偏倚风险评估工具ROBINS-S的标准，对纳入研究进行偏倚风险评估。
结果：纳入研究中考来维仑初始或二线治疗患者总计94例，有效63例，考来维仑治疗BAD的初始治疗总有效率为61.2%，二线治疗总有效率为53.3%，森林图合并有效率为60%（95%CH为0.34-0.86；12=86.57%，@<0.05,存在异质性）。
汇总考来维仑不良反应发生率为6%（95%CH为0.00-0.18；I2=51.74%，@=0.13，存在异质性）。
结论:考来维仑对BAD，包括考来烯胺治疗失败后的BAD治疗安全有效。
目前由于成本因素等，临床上多将考来维仑用于二线治疗，其有效性和安全性需要更多临床试验研究观察。
&关键词'胆汁酸性腹泻；考来维仑；考来烯胺；Meta分析&中图分类号］R574.62&文献标识码］A&文章编号］1671-6264（2020）06-0806-06doi：10.3969/j.issn.1671-6264.2020.06.018A Meta-analysis:efficacy and safety of colesevelamfor the treatment of bile acid diarrheaYANG Nan1，GAO Jie1，LIU Juan2，HUANG Rong2，CHEN Hong2（1.School of'Medicine，Southeast University，Nanjing210009，China； 2.Department of'Gastroenterology，Zhongda Hospital，Sootheass University，Nanjing210009，China）&Abstract］Objective:To analyze and evaluate the efficacy and safete of colesevelam，a new generation of bile acid sequeWdn-for treating bite acid diarrhex（BAD），by Meta-analysis-to asess the dXerences between colesevelam and cholestyramine X four aspects:dieg form，dosage，adverse dieg exction（ADR）and pece. Methods:StudXs were collected fem PubMed，Web l science，Medline，EMBASE，Cochrane librag，CNKI and WanFang Data.，and papers studying patients with bite acid diarrhex using colesevelam were included.We calculated the overall response rate and the incidence of ADR of colesevelam based on metg-ynalysis by Statu14.0.The risk of bias of the included studies was evaluated with ROBINS-，a tool designed for assessing the tsk of bias in &收稿日期］2020-06-22&修回日期］2020-11-11&作者简介］杨楠（1995-），女，江苏淮安人，在读硕士研究生。
维生素D与甲状腺疾病的相关研究进展
维生素D与甲状腺疾病的相关研究进展王君;韩亚玲【摘要】维生素D在人体骨钙代谢平衡中具有重要作用,同时还具有骨骼外作用,它是一种新免疫调节激素,几乎在所有身体组织中均可能产生影响,其中维生素D与甲状腺疾病的关系密切.目前,国内外对Graves病及桥本甲状腺炎的基础及临床研究较为关注,尤其是维生素D缺乏与其患病率有一定的相关性,但其在预防及治疗上的价值仍需进一步研究.同时,虽然维生素D在抗肿瘤治疗中的作用已被认可,但其与甲状腺癌的研究相对较少,未来需要广泛的试验来探索两者之间的关系及作用机制.【期刊名称】《医学综述》【年(卷),期】2018(024)021【总页数】6页(P4245-4249,4255)【关键词】甲状腺疾病;维生素D;25-羟维生素D【作者】王君;韩亚玲【作者单位】保定市第一中心医院内分泌科,河北保定071000;保定市第一中心医院内分泌科,河北保定071000【正文语种】中文【中图分类】R581维生素D属于类固醇化合物，其不仅是人体必需的一种脂溶性维生素，也是一种重要的激素前体。
随着人们对维生素D认识的不断加深，目前发现除维持钙磷平衡和骨骼健康外，维生素D还可以在各种非骨骼疾病中发挥作用，可影响多种细胞的增殖、分化和凋亡等过程，调节免疫系统，是一种新的免疫调节激素。
此外，维生素D可通过调节各种免疫炎性细胞的分化，改变其细胞因子谱，从而影响免疫炎症反应进程。
目前，维生素D在肌肉、心血管、糖尿病、癌症、自身免疫和炎症反应等中的作用逐渐被关注，而其与甲状腺疾病的关系成为研究热点。
在常见的甲状腺疾病中，如Graves病、桥本甲状腺炎(Hashimoto′s thyroiditis, HT)等，在发病过程中常有免疫因素的参与，其生物学作用是通过维生素D受体(vitaminD receptor，VDR)蛋白所介导。
多个研究表明，维生素D缺乏和(或)VDR基因多态性可影响免疫细胞的凋亡，导致甲状腺损伤[1-3]。
爪哇伪枝藻胞外多糖诱导皮肤癌细胞A431凋亡的研究
第32卷第6期水生生物学报Vol .32,No.62008年11月ACT A HY DROB I OLOGICA SI N ICANov .,2008 收稿日期:2006211215;修订日期:2007210212基金项目:国家自然科学基金(30770395;30370112);国家载人航天工程计划;内蒙古发改委与武汉市科技局重大攻关计划;中国科学院水生所领域前沿项目资助作者简介张宏(—),男,安徽金寨人;在读硕士研究生;主要研究方向环境毒理学。
2z _@6通讯作者胡春香,2x @D O I 号:1013724/SP 1J 1000012008160874爪哇伪枝藻胞外多糖诱导皮肤癌细胞(A431)凋亡的研究张 宏 马红樱 张德禄 吕 莹 王高鸿陈 坤 刘永定 胡春香(中国科学院水生生物研究所,武汉 430072)摘要:为探讨爪哇伪枝藻胞外多糖(Extrace llular poly me ric substance s of Scytone m a javanicu m ,EPS)诱导人表皮癌A431细胞凋亡及其对凋亡相关基因caspase 23、bcl 22和bax 表达的影响,本实验利用M TT 法检测细胞生长抑制情况;HE 染色法及透射电镜进行形态学观察;单细胞凝胶电泳法(SCG E /彗星电泳)分析DN A 受损情况;免疫组织化学法检测细胞内ca s pase 23、bc l 22和bax 表达水平。
结果显示EPS 能显著抑制A431细胞增殖,并呈时间和剂量依赖性,作用96h 的半数抑制浓度I C 50为4125m g/mL,并出现细胞凋亡的形态学改变;彗星电泳结果与对照相比6m g/mL EPS 作用48h 能引起A431细胞DNA 严重损伤;免疫组织化学检测发现6mg /mL EPS 作用72h 能显著上调A431细胞内凋亡相关基因caspa s e 23和bax 的表达,而下调bcl 22的表达。
塞来昔布联合西妥昔单抗对人肠癌HCT-116细胞株生物学行为的影响
塞来昔布联合西妥昔单抗对人肠癌HCT-116细胞株生物学行为的影响林梦心;陈强;陈奕贵;陈慧菁;范芳;施纯玫【摘要】Objective To study the synergistic effect of cyclooxygenase-2 inhibitor Celecoxib and Epidermal growth factor receptor (EGFR) monoclonal antibody Cetuximab on human colorectal cancer cell line HCT-116. Methods K-ras gene of HCT-116 cell line was detected by Sanger sequencing. Cells were divided into control group, Celecoxib group, Cetuximab group and combined group. MTT assay was applied to determine the viability of colorectal cancer cell HCT-116, the cell cycle changes were analyzed by flow cytometry ,and wound healing assay was performed to assess the effects of drugs on cell migration. Results K-ras gene was wild type at 12 codon and mutation at 13 codon in HCT-116 cell line. The celecoxib and cetuximab only inhibited proliferation of HCT-116 in a dose-dependent manner, The combination of celecoxib and cetuximab can decrease the proliferation of HCT-116 with a synergistic action; celecoxib and the combination significantly inhibited the ability of cell migration and induced Go/G1 phase arrested(P<0. 05). Conclusion The proliferation of HCT-116 cell could be inhibited by celecoxib and cetuximab only, both drugs have synergistic effects.%目的观察环氧合酶-2抑制剂塞来昔布联合表皮生长因子受体单克隆抗体西妥昔单抗对人肠癌HCT-116细胞株生物学行为的影响.方法 Sanger测序法检测肠癌HCT-116细胞株的K-ras 基因有无突变;塞来昔布、西妥昔单抗单独或联合作用于HCT-116细胞株,四甲基偶氮唑盐(MTT)法检测细胞增值抑制率,细胞划痕实验检测细胞的迁移能力,流式细胞术检测各组细胞的周期分布.结果HCT-116细胞株K-ras基因12位点为野生型、13位点发生突变;塞来昔布及西妥昔单抗对HCT-116细胞的增殖抑制作用均呈剂量依赖性,两药联用可明显抑制HCT-116细胞的增殖;塞来昔布组和联合用药组均能明显抑制HCT-116细胞的迁移能力,而西妥昔单抗对细胞的迁移能力无明显抑制作用;塞来昔布组及联合用药组使细胞发生明显的G0/G1期阻滞(P<0.05).结论塞来昔布与西妥昔单抗单药可抑制肠癌HCT-116细胞的生长,两者联用具有协同作用.【期刊名称】《福建医科大学学报》【年(卷),期】2012(046)006【总页数】7页(P385-391)【关键词】西妥昔单抗;塞来昔布;药物疗法,联合;HCT-116细胞株;表皮生长因子受体;环氧合酶-2【作者】林梦心;陈强;陈奕贵;陈慧菁;范芳;施纯玫【作者单位】福建医科大学,协和临床医学院,福州,350001;福建医科大学,附属协和医院,肿瘤内科,福州,350001;福建省肿瘤转化医学重点实验室,福州,350001;福建医科大学,教学医院,福建省肿瘤医院,肿瘤内科,福州,350014;福建医科大学,教学医院,福建省肿瘤医院,内科研究室,福州,350014;福建医科大学,教学医院,福建省肿瘤医院,药理研究室,福州,350014;福建省肿瘤转化医学重点实验室,福州,350001;福建医科大学,教学医院,福建省肿瘤医院,肿瘤内科,福州,350014【正文语种】中文【中图分类】R453;R735.3;R329.25;R916.4随着肿瘤分子生物学的发展，结直肠癌的药物治疗进入分子靶向治疗时代。